NEW YORK – Danish medical technology firm ViroGates will be an appointed European distributor for Qiagen's aLF lateral flow test reader under a distribution and license agreement, the companies said today.
Financial and other terms of the deal were not disclosed.
Qiagen's aLF is a CE-IVD-marked open reader platform that features a touch screen display, internal barcode scanner, and universal test cassette holder, making it capable of accurately reading every lateral flow test format.
ViroGates said it has validated the instrument for use with its suPARnostic Quick Triage product, which measures the soluble urokinase plasminogen activator receptor (suPAR) protein in the bloodstream to help make discharge determinations for patients in emergency settings. The assay will be included in the aLF test menu, and as such will benefit from existing aLF reader placements and shared marketing efforts, the companies said.
"This step marks an even closer collaboration with Qiagen and also a much better product offering for our clinical customers at the hospitals who can now run several tests on the reader and enjoy a much simpler integration with existing lab information systems," ViroGates CEO Jakob Knudsen said in a statement. "The suPARnostic software solutions will be available to customers on the aLF readers shortly and we expect a significant pull effect from this in the marketplace."